Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

11. Dezember 2022 10:00 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid

HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster...
04. November 2021 16:05 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update

- Entered into additional licensing agreement with The University of Texas MD Anderson Cancer Center for use of CaspaCIDe® safety switch technology - - Charity Scripture, MS, PharmD, appointed Chief...
01. September 2021 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum and MD Anderson Announce Additional License Agreement for Use of CaspaCIDe® Safety Switch

HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas...
12. August 2021 16:05 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports Second Quarter 2021 Financial Results and Provides Operational Update

- Entered into a licensing agreement with two leading oncology research and treatment centers for use of CaspaCIDe® safety switch technology - - Enrollment continuing in Phase 1/2 dose-escalation...
28. Juni 2021 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Enters License Agreement with UNC Lineberger and Mass General for Use of CaspaCIDe® Safety Switch

HOUSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced it has...
17. Mai 2021 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Reports First Quarter 2021 Financial Results and Provides Operational Update

HOUSTON, May 17, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today reported financial...
04. März 2021 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Announces First Reported Use of CaspaCIDe® Safety Switch to Mitigate CAR-T Cell Toxicity

HOUSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the...
11. Dezember 2019 07:30 ET | Quelle: Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals Licenses Its CaspaCIDe® Safety Switch to MD Anderson

HOUSTON, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The...